Nemaura Medical price target lowered to $2.50 from $7 at H.C. Wainwright

H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Nemaura Medical to $2.50 from $7 and keeps a Buy rating on the shares. The firm expects the company to ramp up revenue via global partnerships in the coming years. but says its original projections for the sales trajectory may be too optimistic.